Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience
Dabrafenib is a potent BRAF-kinase inhibitor. Its activity was evaluated on 40 consecutive metastatic melanoma patients (pts) harboring the V600BRAF mutations. Dabrafenib was administered orally at the dosage of 150 mg b.i.d. daily. ORR was 82%, with 7% CR, 62% PR, 13% SD and 18% PD. The median PFS...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Cancer Intelligence
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778691/ |
| id |
pubmed-4778691 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-47786912016-03-15 Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience Cocorocchio, E Gandini, S Alfieri, S Battaglia, A Pennacchioli, E Tosti, G Spadola, G Barberis, M Leo, M Di Riviello, C Pala, L Intelisano, A Martinoli, C Ferrucci, PF Clinical Study Dabrafenib is a potent BRAF-kinase inhibitor. Its activity was evaluated on 40 consecutive metastatic melanoma patients (pts) harboring the V600BRAF mutations. Dabrafenib was administered orally at the dosage of 150 mg b.i.d. daily. ORR was 82%, with 7% CR, 62% PR, 13% SD and 18% PD. The median PFS and OS were seven and 17 months, respectively (median follow-up: 8.5 months). Increased risk of progression was found in pts with elevated LDH, ECOG PS >1 and more than two metastatic sites. Grade 3–4 adverse events were recorded in 4 pts. In this retrospective analysis, Dabrafenib confirmed its role as the standard clinical option in metastatic melanoma pts. Cancer Intelligence 2016-03-03 /pmc/articles/PMC4778691/ /pubmed/26981153 http://dx.doi.org/10.3332/ecancer.2016.624 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Cocorocchio, E Gandini, S Alfieri, S Battaglia, A Pennacchioli, E Tosti, G Spadola, G Barberis, M Leo, M Di Riviello, C Pala, L Intelisano, A Martinoli, C Ferrucci, PF |
| spellingShingle |
Cocorocchio, E Gandini, S Alfieri, S Battaglia, A Pennacchioli, E Tosti, G Spadola, G Barberis, M Leo, M Di Riviello, C Pala, L Intelisano, A Martinoli, C Ferrucci, PF Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience |
| author_facet |
Cocorocchio, E Gandini, S Alfieri, S Battaglia, A Pennacchioli, E Tosti, G Spadola, G Barberis, M Leo, M Di Riviello, C Pala, L Intelisano, A Martinoli, C Ferrucci, PF |
| author_sort |
Cocorocchio, E |
| title |
Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience |
| title_short |
Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience |
| title_full |
Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience |
| title_fullStr |
Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience |
| title_full_unstemmed |
Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience |
| title_sort |
dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience |
| description |
Dabrafenib is a potent BRAF-kinase inhibitor. Its activity was evaluated on 40 consecutive metastatic melanoma patients (pts) harboring the V600BRAF mutations. Dabrafenib was administered orally at the dosage of 150 mg b.i.d. daily. ORR was 82%, with 7% CR, 62% PR, 13% SD and 18% PD. The median PFS and OS were seven and 17 months, respectively (median follow-up: 8.5 months). Increased risk of progression was found in pts with elevated LDH, ECOG PS >1 and more than two metastatic sites. Grade 3–4 adverse events were recorded in 4 pts. In this retrospective analysis, Dabrafenib confirmed its role as the standard clinical option in metastatic melanoma pts. |
| publisher |
Cancer Intelligence |
| publishDate |
2016 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778691/ |
| _version_ |
1613547634738331648 |